Research Status of Quercetin's Cardiovascular Protective Effects and Its Novel Dosage Forms
With the development and utilization of traditional Chinese medicine, quercetin and its derivatives have been discovered in various Chinese medicinal materials and foods.
August 20, 2025
by Xiaonisha
The Bitter Medicine is Good for Health: Research Progress on the Components and Pharmacological Activities of Coptis Chinensis
Coptis chinensis, a perennial herbaceous plant of the Ranunculaceae family, is also known as "Wei Lian," "Yun Lian," "Ya Lian," "Ji Zhuazhao Lian," and so on.
July 2, 2025
by Xiaomichong
The protective effect of soluble guanylate cyclase activators on the cardiovascular system and their therapeutic mechanism for HFpEF
The impairment of the nitric oxide (NO) pathway is closely related to various cardiovascular diseases, such as heart failure, hypertension, and pulmonary hypertension. NO donor drugs or inhaled NO have significant limitations in clinical treatment.
July 17, 2024
by Xiaomichong
Clinical Decision Support May Cut Cardiovascular Disease Risk
Use of clinical decision support systems (CDSSs) is associated with improvements in reversible risk for cardiovascular disease.
February 10, 2022
by drugs.com
Midlife CV Conditions, Risk Factors Linked to Cognitive Decline
Midlife cardiovascular conditions and risk factors are associated with cognitive decline, with stronger associations for women, according to a study published online Jan. 5 in Neurology.
January 5, 2022
by drugs
Amgen, Owkin Use AI to Improve Cardiovascular Risk Prediction
Study demonstrates the ability of AI to improve the way clinicians predict patients' risk of suffering major cardiovascular events.
December 17, 2021
by contractpharma
Birth Order, Family Size May Affect Heart Health
A new Swedish study found that first-born children had a lower risk of heart attacks and strokes than their younger brothers and sisters. But having many siblings was associated with an increased risk of such cardiovascular events.
May 27, 2021
by drugs
Intensive BP Lowering Cuts Major Adverse CV Events, Mortality
Intensive blood pressure treatment targeting systolic blood pressure <120 mm Hg results in lower rates of major adverse cardiovascular events and lower all-cause mortality than a standard treatment target among patients at increased cardiovascular risk
May 21, 2021
by drugs
MHRA authorises Amarin’s heart drug Vazkepa
Amarin’s Vazkepa has received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment to reduce the risk of cardiovascular (CV) events in high-risk patients.
April 23, 2021
by pharmatimes
Takeda to divest select assets in China to Hasten Biopharmaceutic for $322 mn
Takeda Pharmaceutical Company has entered into an agreement to divest a portfolio of non-core prescription pharma products sold in China to Hasten Biopharmaceutic (China).
December 22, 2020
by expresspharma
Zydus Cadila gets tentative US FDA approval for Dapagliflozin Tablets
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus.
October 30, 2020
by expresspharma
Takeda sells select non-core assets in Europe to Cheplapharm for about $562 mn
Portfolio includes prescription products in Takeda’s cardiovascular/metabolic and anti-inflammatory therapeutic areas along with calcium.
September 17, 2020
by expresspharma